trial
as of 2026-07-01A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCTId NCT05686239
at a glance
Phase 2 · Completed
Enrollment 242 (actual)
Sponsored by Recognify Life Sciences
Primary completion 2025-04-09
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
242 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-12-08
Primary completion
2025-04-09
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Recognify Life SciencesLead Sponsor
Investigators
1
Gary Walker, PhDStudy Director
Sites
36 total
Culver City, United StatesGarden Grove, United StatesLafayette, United StatesOceanside, United StatesOrange, United StatesTorrance, United StatesHialeah, United StatesMiami, United StatesMiami Lakes, United StatesAtlanta, United StatesAugusta, United StatesGaithersburg, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
242
Phase
PHASE2
Primary Completion Date
2025-04-09
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication
investigator
person